Miris reports Q3 sales growth

Miris reports Q3 sales growth

Medtech company Miris reports sales growth for Q3, continuing the positive trend from the first half of the year. Sales increased by as much...
Lipum

Lipum stepped into clinical stage in Q3

In Lipum's quarterly report, CEO Einar Pontén says that more is going on at the company than ever before. Their drug candidate SOL-116 recently...
Prostate cancer

Swedish innovations in the fight against prostate cancer

November sheds light on one of the deadliest cancers among men – prostate cancer. In this article, BioStock draws attention to the disease and...
Arcede Pharmas toxicological study shows RCD405 is well tolerated

Arcede Pharma’s RCD405 well tolerated

Lund-based Arcede Pharma is working hard to complete the preclinical work on the drug candidate RCD405. The company now reports the first part of...
PK-studie i fokus under Emplicures tredje kvartal

PK study in focus during Emplicure’s third quarter

During Emplicure's third quarter, the focus has been on the pharmacokinetic study with the company's main project Empli03, which is aimed at patients with...
Jan Holgersson

Idogen strengthens the Board with Jan Holgersson

Idogen strengthens the Board of Directors with Professor Jan Holgersson, who has extensive experience in immunology and who has been a member of the...
Mikeael Lindstam, Aptahem

Aptahem’s CEO on upcoming milestones

Aptahem has taken several steps forward in 2022. Recently, the biotech company passed a milestone with the start of the clinical phase I study...
CLS vd Dan Mogren i BioStocks studio i Lund

CLS on a Q3 characterised by US-advancement

Medtech Clinical Laserthermia Systems, CLS, can look back on a third quarter characterised by advancement on the US market. In September, the company received...

PHI on the alliance for cell-based biomanufacturing

Phase Holographic Imaging, PHI, recently created a US-based alliance for advancing cell-based biomanufacturing with Wake Forest Institute for Regenerative Medicine, BioSpherix, QIAGEN and global...
Elicera iTANK partnering intensifies

Elicera’s CEO: “iTANK partnering is intensifying”

Elicera Therapeutics is in an advantageous position, both in terms of financial flexibility and the ability to enter into new collaboration agreements. The cell...